VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

Not Recruiting

Trial ID: NCT01289210


This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.

Official Title

A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas

Stanford Investigator(s)

Manali Patel
Manali Patel

Associate Professor of Medicine (Oncology)

Ash A. Alizadeh, MD/PhD
Ash A. Alizadeh, MD/PhD

Moghadam Family Professor


Major Inclusion Criteria:

   - low grade B cell lymphoma

   - 1 or more sites of disease appropriate for intratumoral injection

   - measurable disease other than the injection site

   - Performance Status of 1 or better

   - Adequate bone marrow, renal and hepatic function

   - No active autoimmune disease or systemic immunosuppressive drugs

   - Life expectancy > 4 months

Exclusion Criteria:

   - Known HIV

   - Known brain metastases

   - Malignancy within last 5 yrs (basal cell or non-invasive squamous cell carcinoma OK)

   - Anticoagulation therapy other than 325mg QD ASA

   - Significant cardiovascular disease

   - Pregnant or nursing


drug: VTX-2337 plus radiotherapy

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Lori Richards

New Trial Alerts

Receive email alerts when trials open to patients.